

Olga MartÃ-nez-SÃ;ez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1766238/publications.pdf>

Version: 2024-02-01

14
papers

582
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

743
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2022, 16, 69-87.	4.6	24
2	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. <i>Biomedicine Hub</i> , 2022, 7, 11-16.	1.2	2
3	Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice. <i>Cancer Research</i> , 2022, 82, P4-11-28-P4-11-28.	0.9	0
4	Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3). <i>Cancer Research</i> , 2022, 82, PD13-04-PD13-04.	0.9	2
5	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. <i>Cancer Research</i> , 2022, 82, P4-07-08-P4-07-08.	0.9	2
6	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638482.	2.8	16
7	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. <i>Journal of Clinical Oncology</i> , 2021, 39, 1458-1467.	1.6	73
8	Current and Future Management of HER2-Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 594-604.	2.9	102
9	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.1	7
10	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	5.0	175
11	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
12	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	12.8	67
13	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. <i>Clinical Colorectal Cancer</i> , 2019, 18, e287-e293.	2.3	15
14	Primary Neuroendocrine Tumor of the Parotid Gland: A Case Report and a Comprehensive Review of a Rare Entity. <i>Case Reports in Otolaryngology</i> , 2016, 2016, 1-5.	0.2	5